NCT03654196View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

September 21, 2018

Study Completion Date

September 21, 2018

Conditions
Acute Bronchitis
Interventions
DRUG

HL301(Experimental)

Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]

DRUG

Umkamin(Active Comparator)

Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]

Trial Locations (1)

130-872

Kyung Hee University Hospital, Seoul

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients | Biotech Hunter | Biotech Hunter